Twist Bioscience : Fiscal 2024 2Q Financial Results

Fiscal 2024 2Q Financial Results

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Agenda

Welcome

Angela Bitting

SVP, Corporate Affairs; Chief ESG Officer

Quarterly Highlights

Emily Leproust

Chief Executive Officer

Financial and Operational Performance

Adam Laponis

Chief Financial Officer

Milestones

Emily Leproust

Chief Executive Officer

Q&A Session

2

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Legal Disclaimers

This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, financial guidance for fiscal 2024 and the second fiscal quarter of 2024, statements regarding Twist Bioscience's path to profitability, future growth, expansion, market share gains and Twist Bioscience's other expectations regarding its future operations plans and financial performance, timing of end to end workflow for DNA data storage, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

The presentation also contains supplemental financial information determined by methods other than in accordance with U.S. generally accepted accounting principles ("GAAP"). A reconciliation of these non-GAAP financial measures may be found on page 15 of this presentation.

3

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Highlights from the Quarter

$75.3 M	$93.2 M	41%
Revenue	Orders	Gross Margin
Beat guidance	Strong orders	Beat guidance
of $70-71 M		of 39%

4

1

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Life Sciences Tools

SYN BIO WRITE

2Q 2024

• $29.8 million in revenue
• $44.9 million in orders
• More than 1,600 Express Genes orders
• Shipped 193,000 genes

Next Up

• Wilsonville, OR manufacturing launch
• Express Genes
  Additional Express products 500bp oligo synthesis
  RNA GMP

5	*Limited launch initiated November 13, 2023; full launch on January 24, 2024

2	Life Sciences Tools
NGS READ

2Q 2024

and CONFIDENTIAL	• $40.8 million in revenue
PROPRIETARY|
	•	customers
BIOSCIENCE		36% of rev from top 10 NGS
•	Launched several products
	•	$42.5 million in orders
| TWIST

Next Up

• RNA sequencing workflow
• Liquid biopsy growth (ongoing)
• MRD growth (ongoing)
• Regulated products
  SNP microarray conversion Advanced library prep

6	For Research Use Only. Not for use in diagnostic procedures

3

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

BIOPHARMA SOLUTIONS

2Q 2024

Next Up

		ü Integrated offering
		Scaling orders
•	$4.7 million in revenue	Scaling revenue
•	$5.8 million in orders

7	For Research Use Only. Not for use in diagnostic procedures

3

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

BIOPHARMA SOLUTIONS

Combined Biopharma Business

Broad	Varied
Disease Indications
Modalities
Cancer, Neurology, Immuno-
mAbs, Bispecific Antibodies, VHH,
oncology, Infectious Disease,
ADC, Protein Engineering, More
Canine / Feline, Other	Poised to Deliver
	Quarterly Revenue

	67	34
334	Active	Programs
Programs	Started
Partners	883	69
	Completed	Milestones/
	Programs	Royalties

8

4

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Premium Solutions

DNA DATA STORAGE

Reinventing Archive Storage

• Refining enzymatic synthesis: lowest cost, aqueous-based, shippable system
• Collaborating with Fortune 500 company on industrial-grade
  CODEC
• Demonstrated end-to-end Gigabyte workflow
• Launching early access Terabyte Century Archive solution planned in CY25

Target Early Access Customers

MEDIA /	HEALTHCARE	PRESERVATION	GOVERNMENT
ENTERTAINMENT		(CULTURAL HERITAGE)

Century Archive

Solution

Valuable Optionality at Multiple Time Points

Internal Development

External Investment

Strategic Partner

9

Strong Quarterly Revenue Growth

$ in Millions

$75.3

$71.5

$66.9

Biopharma	$63.7
NGS	$60.2
	$57.3
SynBio	$56.1
$54.2
	$48.1

CONFIDENTIAL

$32.4

$42.0

$38.0

$35.0

$31.2

TWIST BIOSCIENCE| PROPRIETARY and

$6.5

$28.2

$21.2

$17.2 $19.3

$15.7

$13.6 $13.6

$11.5

$8.4

|

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

10